{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T22:02:23Z","timestamp":1794780143340,"version":"4.9.1"},"reference-count":30,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T00:00:00Z","timestamp":1768521600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostics"],"abstract":"<jats:p>Background: Urine cytology remains widely used for surveillance of non-muscle-invasive bladder cancer despite well-known limitations in sensitivity, especially for low-grade tumors. Uromonitor\u00ae, a molecular assay detecting TERT promoter, FGFR3, and KRAS mutations in voided urine, has emerged as a promising adjunct. To evaluate its suitability for routine use, a consolidated assessment of diagnostic performance and a direct comparison with urine cytology are needed. Methods: We conducted a prospectively registered systematic review (PROSPERO CRD420251173244), synthesizing all available studies that evaluated Uromonitor\u00ae for the detection of urothelial carcinoma of the bladder (UCB). Methodological quality was assessed using the QUADAS-2 framework, and certainty of evidence was evaluated following GRADE for diagnostic tests. Sensitivity was prespecified as the primary endpoint. Comparative datasets were identified, and random-effects meta-analyses were performed for sensitivity, specificity, accuracy, and predictive values (PVs). Results: Across eight cohorts evaluating Uromonitor\u00ae, 832 of 3196 patients (26.0%) had histologically confirmed UCB. Aggregated sensitivity was 0.55 (95% CI 0.52\u20130.58). Specificity was 0.95 (0.94\u20130.96). Accuracy was 0.85 (0.83\u20130.86). PPV was 0.79 (0.76\u20130.82), and NPV was 0.86 (0.84\u20130.87). Across seven paired datasets, urine cytology demonstrated a sensitivity of 0.42, a specificity of 0.91, an accuracy of 0.78, a PPV of 0.64, and an NPV of 0.81. Pooled odds ratio for sensitivity was 3.16 (0.73\u201313.76), while diagnostic accuracy yielded 1.71 (1.01\u20132.90). Differences in specificity and NPV were not statistically significant, whereas the PPV favored Uromonitor\u00ae, reaching statistical significance in pooled analyses. Conclusions: Uromonitor\u00ae demonstrates higher sensitivity and improved accuracy compared with urine cytology, although current performance remains insufficient for stand-alone surveillance. The sensitivity estimate showed very low certainty due to pronounced heterogeneity, underscoring the need for careful interpretation. With advancing DNA recovery methods, incorporation of droplet digital PCR, and rigorous evaluations in prospective multicenter studies, Uromonitor\u00ae may become an integral element of risk-adapted follow-up strategies.<\/jats:p>","DOI":"10.3390\/diagnostics16020285","type":"journal-article","created":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T09:28:12Z","timestamp":1768555692000},"page":"285","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Diagnostic Performance and Clinical Utility of the Uromonitor\u00ae Molecular Urine Assay for Urothelial Carcinoma of the Bladder: A Systematic Review and Diagnostic Accuracy Meta-Analysis"],"prefix":"10.3390","volume":"16","author":[{"given":"Julio Ruben","family":"Rodas Garzaro","sequence":"first","affiliation":[{"name":"Department of Urology, St. Elisabeth Hospital Straubing, Brothers of Mercy Hospital, 94315\u00a0Straubing, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-3365-1563","authenticated-orcid":false,"given":"Anton","family":"Kravchuk","sequence":"additional","affiliation":[{"name":"Department of Urology, St. Elisabeth Hospital Straubing, Brothers of Mercy Hospital, 94315\u00a0Straubing, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Burger","sequence":"additional","affiliation":[{"name":"Department of Urology, Caritas St. Josef Medical Center, University of Regensburg, 93053 Regensburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4197-6643","authenticated-orcid":false,"given":"Ingmar","family":"Wolff","sequence":"additional","affiliation":[{"name":"Department of Urology, University Medicine Greifswald, 17475 Greifswald, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steffen","family":"Lebentrau","sequence":"additional","affiliation":[{"name":"Department of Urology, Werner Forssmann Hospital, 16225 Eberswalde, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Rubio-Briones","sequence":"additional","affiliation":[{"name":"Department of Urology, Hospital VITHAS 9 de Octubre, 46015 Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1867-0486","authenticated-orcid":false,"given":"Jo\u00e3o Paulo","family":"Br\u00e1s","sequence":"additional","affiliation":[{"name":"Instituto de Investiga\u00e7\u00e3o e Inova\u00e7\u00e3o em Sa\u00fade (i3S), Universidade do Porto, 4200-135 Porto, Portugal"},{"name":"Instituto de Patologia e Imunologia Molecular (Ipatimup), Universidade do Porto, 4200-135 Porto, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0211-0636","authenticated-orcid":false,"given":"Christian","family":"Gilfrich","sequence":"additional","affiliation":[{"name":"Department of Urology, St. Elisabeth Hospital Straubing, Brothers of Mercy Hospital, 94315\u00a0Straubing, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Siepmann","sequence":"additional","affiliation":[{"name":"Department of Urology, St. Elisabeth Hospital Straubing, Brothers of Mercy Hospital, 94315\u00a0Straubing, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sascha","family":"Pahernik","sequence":"additional","affiliation":[{"name":"Department of Urology, Nuremberg General Hospital, Paracelsus Medical University, 90419 Nuremberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel S.","family":"Merseburger","sequence":"additional","affiliation":[{"name":"Department of Urology, University Hospital Schleswig-Holstein, Campus L\u00fcbeck, 23538 L\u00fcbeck, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Heidenreich","sequence":"additional","affiliation":[{"name":"Department of Urology, Uro-Oncology, Robot-Assisted, and Specialized Urologic Surgery, University Hospital Cologne, 50937 Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"May","sequence":"additional","affiliation":[{"name":"Department of Urology, St. Elisabeth Hospital Straubing, Brothers of Mercy Hospital, 94315\u00a0Straubing, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,1,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.eururo.2024.07.027","article-title":"European Association of Urology Guidelines on Non\u2013muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ)\u2014A Summary of the 2024 Guidelines Update","volume":"86","author":"Gontero","year":"2024","journal-title":"Eur. Urol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1097\/JU.0000000000003846","article-title":"Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA\/SUO Guideline: 2024 Amendment","volume":"211","author":"Holzbeierlein","year":"2024","journal-title":"J. Urol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.annonc.2022.01.075","article-title":"Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Moschini","year":"2022","journal-title":"Ann. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Pan, W., Xing, J., Chen, X., Xue, R., Xu, G., Li, S., Yi, H., Jin, B., Wan, X., and Sang, X. (2025). Urinary biomarkers in cancer detection: Explorations, advancements, challenges, and future directions. Int. J. Surg., ahead of print.","DOI":"10.1097\/JS9.0000000000003919"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Zhang, D., Chen, B., Ye, J., Bai, Y., and Han, P. (2025). Integrated assessment of non-invasive diagnostic tools for bladder cancer: A network meta-analysis. Front. Oncol., 15.","DOI":"10.3389\/fonc.2025.1649420"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3892\/ijo.2025.5724","article-title":"Unleashing the power of urine-based biomarkers in diagnosis, prognosis and monitoring of bladder cancer (Review)","volume":"66","author":"Wan","year":"2025","journal-title":"Int. J. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.euo.2021.10.003","article-title":"Diagnostic Accuracy of Novel Urinary Biomarker Tests in Non\u2013muscle-invasive Bladder Cancer: A Systematic Review and Network Meta-analysis","volume":"4","author":"Laukhtina","year":"2021","journal-title":"Eur. Urol. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Kravchuk, A.P., Wolff, I., Gilfrich, C., Wirtz, R.M., Soares, P., Braun, K.-P., Brookman-May, S.D., Kollitsch, L., Hauner, K., and Burchardt, M. (2024). Urine-Based Biomarker Test Uromonitor\u00ae in the Detection and Disease Monitoring of Non-Muscle-Invasive Bladder Cancer\u2014A Systematic Review and Meta-Analysis of Diagnostic Test Performance. Cancers, 16.","DOI":"10.3390\/cancers16040753"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Batista, R., Vinagre, J., Prazeres, H., Sampaio, C., Peralta, P., Concei\u00e7\u00e3o, P., Sismeiro, A., Le\u00e3o, R., Gomes, A., and Furriel, F. (2019). Validation of a Novel, Sensitive, and Specific Urine-Based Test for Recurrence Surveillance of Patients with Non-Muscle-Invasive Bladder Cancer in a Comprehensive Multicenter Study. Front. Genet., 10.","DOI":"10.3389\/fgene.2019.01237"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Sieverink, C.A., Batista, R.P.M., Prazeres, H.J.M., Vinagre, J., Sampaio, C., Le\u00e3o, R.R., M\u00e1ximo, V., Witjes, J.A., and Soares, P. (2020). Clinical Validation of a Urine Test (Uromonitor-V2\u00ae) for the Surveillance of Non-Muscle-Invasive Bladder Cancer Patients. Diagnostics, 10.","DOI":"10.3390\/diagnostics10100745"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1097\/JU.0000000000004335","article-title":"Uromonitor: Clinical Validation and Performance Assessment of a Urinary Biomarker Within the Surveillance of Patients with Nonmuscle-Invasive Bladder Cancer","volume":"213","author":"Ramos","year":"2025","journal-title":"J. Urol."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Azawi, N., V\u00e1squez, J.L., Dreyer, T., Guldhammer, C.S., Al-Juboori, R.M.S., Nielsen, A.M., and Jensen, J.B. (2023). Surveillance of Low-Grade Non-Muscle Invasive Bladder Tumors Using Uromonitor: SOLUSION Trial. Cancers, 15.","DOI":"10.3390\/cancers15082341"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1111\/bju.16450","article-title":"Real-world performance of Uromonitor\u00ae in urothelial bladder cancer detection: A multicentric trial","volume":"134","author":"Wolff","year":"2024","journal-title":"BJU Int."},{"key":"ref_14","first-page":"216","article-title":"External validation of the Uromonitor\u00ae-version 2 urine test as a biomarker for optimisation of non-muscle-invasive bladder cancer management","volume":"137","author":"Ramos","year":"2025","journal-title":"BJU Int."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.urology.2024.11.056","article-title":"Performance of Urinary Markers in Patients With Suspicious Cystoscopy During Follow-up of Recurrent Non-muscle Invasive Bladder Cancer: BTA Stat, NMP22 BladderChek, UBC Rapid Test, CancerCheck UBC Rapid VISUAL, and Uromonitor in Comparison to Cytology","volume":"197","author":"Ecke","year":"2025","journal-title":"Urology"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"30617","DOI":"10.1038\/s41598-024-83976-2","article-title":"Diagnostic performance of Uromonitor and TERTpm ddPCR urine tests for the non-invasive detection of bladder cancer","volume":"14","author":"Rabien","year":"2024","journal-title":"Sci. Rep."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jclinepi.2019.11.010","article-title":"Mapping of reporting guidance for systematic reviews and meta-analyses generated a comprehensive item bank for future reporting guidelines","volume":"118","author":"Page","year":"2020","journal-title":"J. Clin. Epidemiol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"m2632","DOI":"10.1136\/bmj.m2632","article-title":"Preferred reporting items for systematic review and meta-analysis of diagnostic test accuracy studies (PRISMA-DTA): Explanation, elaboration, and checklist","volume":"370","author":"Salameh","year":"2020","journal-title":"BMJ"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"111370","DOI":"10.1016\/j.jclinepi.2024.111370","article-title":"Common challenges and suggestions for risk of bias tool development: A systematic review of methodological studies","volume":"171","author":"Tomlinson","year":"2024","journal-title":"J. Clin. Epidemiol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"529","DOI":"10.7326\/0003-4819-155-8-201110180-00009","article-title":"QUADAS-2: A revised tool for the quality assessment of diagnostic accuracy studies","volume":"155","author":"Whiting","year":"2011","journal-title":"Ann. Intern. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jclinepi.2019.02.003","article-title":"GRADE guidelines: 22. The GRADE approach for tests and strategies\u2014From test accuracy to patient-important outcomes and recommendations","volume":"111","author":"Mustafa","year":"2019","journal-title":"J. Clin. Epidemiol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1111\/bju.14808","article-title":"Targeted deep sequencing of urothelial bladder cancers and associated urinary DNA: A 23-gene panel with utility for non-invasive diagnosis and risk stratification","volume":"124","author":"Ward","year":"2019","journal-title":"BJU Int."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1038\/s41379-019-0276-y","article-title":"Incidence and distribution of UroSEEK gene panel in a multi-institutional cohort of bladder urothelial carcinoma","volume":"32","author":"Eich","year":"2019","journal-title":"Mod. Pathol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.clgc.2020.12.003","article-title":"Advances in Biomarkers for Detection, Surveillance, and Prognosis of Bladder Cancer","volume":"19","author":"Henning","year":"2021","journal-title":"Clin. Genitourin. Cancer"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.clgc.2022.12.004","article-title":"Urine Cytology Rarely Escalates Clinical Management in the Surveillance of Non\u2013muscle-Invasive Bladder Cancer","volume":"21","author":"Feiertag","year":"2023","journal-title":"Clin. Genitourin. Cancer"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/j.euf.2025.06.009","article-title":"Urinary Tumor DNA\u2013based Liquid Biopsy in Bladder Cancer Management: A Systematic Review","volume":"11","author":"Lee","year":"2025","journal-title":"Eur. Urol. Focus"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3233\/BLC-230096","article-title":"Noninvasive Tests for Bladder Cancer Detection and Surveillance: A Systematic Review of Commercially Available Assays","volume":"10","author":"Heard","year":"2024","journal-title":"Bladder Cancer"},{"key":"ref_28","first-page":"449.e21","article-title":"Clinical performance of Bladder EpiCheck\u2122 versus voided urine cytology for detecting recurrence of nonmuscle invasive bladder cancer: Systematic review and meta-analysis","volume":"42","author":"Chang","year":"2024","journal-title":"Urol. Oncol. Semin. Orig. Investig."},{"key":"ref_29","first-page":"163.e1","article-title":"Xpert bladder cancer monitor in surveillance of bladder cancer: Systematic review and meta-analysis","volume":"40","author":"Sharma","year":"2022","journal-title":"Urol. Oncol. Semin. Orig. Investig."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Bessa-Gon\u00e7alves, M., Br\u00e1s, J.P., Jesus, T.T., Prazeres, H., Soares, P., and Vinagre, J. (2024). TERTmonitor Efficacy and Performance in Detecting Mutations by Droplet Digital PCR. Genes, 15.","DOI":"10.3390\/genes15111424"}],"container-title":["Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4418\/16\/2\/285\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T09:44:17Z","timestamp":1768556657000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4418\/16\/2\/285"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,16]]},"references-count":30,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["diagnostics16020285"],"URL":"https:\/\/doi.org\/10.3390\/diagnostics16020285","relation":{},"ISSN":["2075-4418"],"issn-type":[{"value":"2075-4418","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,16]]}}}